{
    "clinical_study": {
        "@rank": "31822", 
        "arm_group": [
            {
                "arm_group_label": "Yangzhengxiaoji Capsule combined with CHOP regimen", 
                "arm_group_type": "Experimental", 
                "description": "Yangzhengxiaoji Capsule combined with CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen"
            }, 
            {
                "arm_group_label": "CHOP regimen", 
                "arm_group_type": "Experimental", 
                "description": "CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of Yangzhengxiaoji Capsule\n      Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma."
        }, 
        "brief_title": "Treatment of Diffuse Large B Cell Lymphoma", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Diffuse Large B Cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Age range 14-70 years old; ECOG performance status 0-2; Estimated survival time > 3\n        months Histological confirmed Diffuse large B cell lymphoma(III/IV) None of chemotherapy\n        or radiotherapy has been previously used None of chemotherapy contraindication: hemoglobin\n        \u2265 90 g/dl, neutrophil \u2265 1.5\u00d7109/L, platelet \u2265 100\u00d7109/L, ALT and AST \u2264 2\u00d7ULN, serum\n        bilirubin \u2264 1.5\u00d7ULN, serum creatine \u2264 1.5\u00d7upper limitation of normal (ULN), Serum Albumin\n        \u2265 30g/L At least one measurable lesion None of other serious diseases, cardiopulmonary\n        function is normal Pregnancy test of women at reproductive age must be negative Patients\n        could be followed up None of other relative treatments including the traditional Chinese\n        medicine, immunotherapy,biotherapy except anti-bone metastasis therapy and other\n        symptomatic treatments.\n\n        Exclusion Criteria:\n\n          -  Disagreement on blood sample collection Patients allergic of any of drug in this\n             regimen or with metabolic disorder Pregnant or lactating women Serious medical\n             illness likely to interfere with participation Serious infection Primitive or\n             secondary tumors of central nervous system Chemotherapy or radiotherapy\n             contraindication The evidence of CNS metastasis History of peripheral nervous\n             disorder or dysphrenia patients participating in other clinical trials patients\n             taking other antitumor drugs patients estimated to be unsuitable by investigation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "14 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01949818", 
            "org_study_id": "hnslblzlzx2011-4"
        }, 
        "intervention": [
            {
                "arm_group_label": "Yangzhengxiaoji Capsule combined with CHOP regimen", 
                "description": "Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)Yangzhengxiaoji capsule ,1.56g,Tid,p.o,d7-21, Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.", 
                "intervention_name": "Yangzhengxiaoji capsule combined with CHOP regimen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CHOP regimen", 
                "description": "CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5", 
                "intervention_name": "CHOP regimen", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Doxorubicin", 
                "Vincristine", 
                "Prednisolone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 24, 2013", 
        "location": {
            "contact": {
                "email": "mingzhi_zhang@126.com", 
                "last_name": "Mingzhi Zhanf, Dr", 
                "phone": "13838565629"
            }, 
            "contact_backup": {
                "email": "mingzhi_zhang@126.com", 
                "last_name": "Mingzhi Zhang, Dr", 
                "phone": "13838565629"
            }, 
            "facility": {
                "address": {
                    "city": "Zhengzhou", 
                    "country": "China", 
                    "state": "Henan", 
                    "zip": "450052"
                }, 
                "name": "Oncology Department of The First Affiliated Hospital of Zhengzhou University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma", 
        "overall_contact": {
            "email": "Mingzhi_zhang@126.com", 
            "last_name": "Mingzhi Zhang, Dr", 
            "phone": "13838565629"
        }, 
        "overall_contact_backup": {
            "email": "Mingzhi_zhang@126.com", 
            "last_name": "Mingzhi zhang, Dr", 
            "phone": "13838565629"
        }, 
        "overall_official": {
            "affiliation": "The First Affiliated Hospital of Zhengzhou University", 
            "last_name": "Mingzhi Zhang, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "up to end of follow-up-phase (approximately 24 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01949818"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zhengzhou University", 
            "investigator_full_name": "Mingzhi Zhang", 
            "investigator_title": "The director of oncology department of the first affiliated hospital", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "overall survival", 
            "safety_issue": "No", 
            "time_frame": "up to the date of death (approximately 5 years)"
        }, 
        "source": "Zhengzhou University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mingzhi Zhang", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}